In vitro cytotoxicity and teratogenicity of norethisterone and levonorgestrel released from hollow nylon monofilaments

Journal of Controlled Release

Volumn 50, Issue 1-3, 1998, Pages 179-186

  Ostad, S Nasser ^a   Malhi, Jaspal S ^b   Gard, Paul R ^a  

^a UNIVERSITY OF BRIGHTON   (United Kingdom)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

Drug delivery; Hormone replacement therapy; Intrauterine device; Levonorgestrel; Norethisterone

Indexed keywords

GESTAGEN; LEVONORGESTREL; NORETHISTERONE; NYLON;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RELEASE; ENDOMETRIUM CELL; FEMALE; FETUS; FETUS CELL; HOLLOW FIBER MEMBRANE; HORMONE SUBSTITUTION; NONHUMAN; PRIORITY JOURNAL; RAT; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; CELLS, CULTURED; CONTRACEPTIVES, ORAL, SYNTHETIC; DRUG DELIVERY SYSTEMS; FEMALE; LEVONORGESTREL; NORETHINDRONE; NYLONS; PREGNANCY; RATS; RATS, WISTAR;

EID: 0032472348     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(97)00132-6     Document Type: Article

References (23)

1. Lewis M.A., Spitzer W.O., Heineman L.A.J., Macrae K.D., Bruppacher R. 3rd generation oral-contraceptives and risk of myocardial infarction - an international case-control study. Br. Med. J. 312:1996;88-90.
2. Spitzer W.O., Lewis M.A., Heineman L.A.J., Thorogood M., Macrae K.D. 3rd Generation oral-contraceptives and risk of venous thromboembolic disorders - an international case-control study. Br. Med. J. 312:1996;83-88.
3. Vessey M.P., McPherson K., Lawless M., Yeates D. Neoplasia of the cervix uteri and contraception - a possible adverse effect of the pill. Lancet. ii:1983;930-934.
4. Meirik O., Adami H.O., Christoffersen T., Lund E. Oral-contraceptive use and breast-cancer in young women - a joint national case-control study in Sweden and Norway. Lancet. 11:1986;650-654.
5. Makkonen M., Saarikoski S., Penttila L. Effects of oestradiol valerate plus two different progestogens on serum-lipids during postmenopausal replacement therapy. Maturitas. 14:1991;43-48.
6. Gambrell R.D., Teran A.Z. Changes in lipids and lipoproteins with long-term oestrogen deficiency and hormone replacement therapy. Am. J. Obstet. Gynecol. 165:1991;307-317.
7. Voigt L.F., Weiss N.S., Chu J., Daling J.R., McKnight B., Vanbelle G. Progestogen supplementation of exogenous oestrogens and the risk of endometrial cancer. Lancet. 338:1991;274-277.
8. Tang G.W.K., Lo S.S.T. Levonorgestrel intrauterine-device in the treatment of menorrhagia in Chinese women-efficacy versus acceptability. Contraception. 51:1995;231-235.
9. Raudaskoski T.H., Lahti E.I., Kauppila A.J., Apajasarkkinen M.A., Laatikainen T.J. Transdermal oestrogen with a levonorgestrel-releasing intrauterine-device for climacteric complaints - clinical and endometrial responses. Am. J. Obstet. Gynecol. 172:1995;114-119.
10. Scommenga A., Pandya G., Christ M., Lee A., Cohen M. Intrauterine administration of progesterone by a slow release device. Fertil. Steril. 21:1970;201-210.
11. Luukkainen T., Allonen H., Haukkamaa M., Lahteenmaki P., Nilsson C.G. 5 years experience with levonorgestrel-releasing IUDs. Contraception. 33:1986;139-148.
12. Reynolds J.P., Hanlon G.W., Gard P.R., Malhi J.S. Nylon hollow fibres as a simple, versatile means of prolonged chlorhexidine and steroid delivery. J. Pharm. Pharmacol. 43(Suppl):1991;90.
13. Reynolds J.P., Hanlon G.W., Malhi J.S., Gard P.R. Local delivery of progesterone to the guinea-pig uterus using hollow nylon fibres. J. Pharm. Pharmacol. 44(Suppl):1992;1083.
14. Toivonen J., Luukkainen T., Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: Three years' comparative experience on levonorgestrel- and copper-releasing intrauterine devices. Obstet. Gynecol. 77:1991;261-264.
15. Wiehle R.D. Establishment of rat endometrial cell lines by retroviral-mediated transfer of immortalising and transforming oncogenes. Oncogene. 5:1990;787-794.
16. Flint O.P., Orton T.C., Ferguson R.A. Differentiation of rat embryo cells in culture: response following acute maternal exposure to teratogens and non-teratogens. J. Appl. Toxicol. 4:1984;109-116.
17. Pakarinen P., Luukkainen T., Laine H., Lahteenmaki P. The effect of local intrauterine levonorgestrel administration on endometrial thickness and uterine blood-circulation. Hum. Reprod. 10:1995;2390-2394.
18. Suhonen S., Holmstrom T., Lahteenmaki P. Three-year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy. Acta Obstet. Gynecol. Scand. 76:1997;145-150.
19. Edgren R.A., Peterson D.A., Jones R.C., Nagra C.L., Smith H., Hughes G.A. Biological effects of synthetic gonanes. Recent Prog. Horm. Res. 22:1996;305-349.
20. Flint O.P., Orton T.C. An in vitro assay for teratogens with cultures of rat embryo midbrain and limb bud cells. Toxicol. Appl. Pharmacol. 76:1984;383-395.
21. Kistler A., Mislin M., Gehric A. Chondrogenesis of limb-bud cells-improved culture method and the effect of the potent teratogen retinoic acid. Xenobiotica. 15:1985;673-679.
22. Janerich D.T. J.M. Piper and D.M., Glebatis, Oral contraceptives and congenital limb-reduction defects. N. Engl. J. Med. 291:1974;697-700.
23. Jacobson B.D. Hazards of norethindrone therapy during pregnancy. Am. J. Obstet. Gynecol. 84:1962;962-968.